What is Alibaba Health Information Technology Altman Z-Score?
Alibaba Health Information TechnologyALBBY +1.12%73 Altman Z-Score is 7.39 as of Jun. 29, 2026, which is 48% below its 10-year median of 14.28. GuruFocus rates ALBBY with a GF Scoreâ„¢ of 73/100 and a GF Valueâ„¢ of $13.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Alibaba Health Information Technology ranks better than 85.08% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 7.34 is strong.
Alibaba Health Information Technology has a Altman Z-Score of 7.39, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
Alibaba Health Information Technology (OTCPK:ALBBY) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alibaba Health Information Technology Altman Z-Score Chart
Alibaba Health Information Technology Altman Z-Score Competitor Comparison
For the Pharmaceutical Retailers subindustry, Alibaba Health Information Technology's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alibaba Health Information Technology Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Alibaba Health Information Technology's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Alibaba Health Information Technology's Altman Z-Score falls into.
Alibaba Health Information Technology Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Alibaba Health Information Technology (ALBBY) has a Altman Z-Score of 7.39 as of Jun. 29, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alibaba Health Information Technology and its competitors. This is 48% below median its historical median of 14.28. Over the past decade, Alibaba Health Information Technology's Altman Z-Score has ranged from 7.34 to 44.78. According to the industry distribution chart, Alibaba Health Information Technology ranks #98 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 14.9%.
Is Alibaba Health Information Technology's Altman Z-Score too high?
Alibaba Health Information Technology's current Altman Z-Score of 7.39 is 48% below median its 10-year median of 14.28. Over the past 10 years, this metric has ranged from a low of 7.34 to a high of 44.78. The Healthcare Providers & Services industry median Altman Z-Score is 2.38. Alibaba Health Information Technology's value of 7.39 is 210.5% above this industry median. Based on the distribution chart, Alibaba Health Information Technology ranks #98 out of 657 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Alibaba Health Information Technology has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alibaba Health Information Technology's Altman Z-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Alibaba Health Information Technology ranks #98 out of 657 companies for Altman Z-Score. This places Alibaba Health Information Technology in the top 15% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.38. Alibaba Health Information Technology's value of 7.39 is 210.5% above this benchmark. Historically, Alibaba Health Information Technology's own Altman Z-Score has ranged from 7.34 to 44.78 over the past decade. While the company's 10-year median is 14.28 vs. the industry median of 2.38, Alibaba Health Information Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.38, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alibaba Health Information Technology's current Altman Z-Score of 7.39 is 210.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alibaba Health Information Technology and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alibaba Health Information Technology's current Altman Z-Score is 7.39, which is 48% below median its own 10-year median of 14.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alibaba Health Information Technology stock overvalued right now?
Based on GuruFocus' analysis, Alibaba Health Information Technology (ALBBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.36, compared to a current price of $7.92 — trading 40.7% below its estimated fair value. The current Altman Z-Score is 7.39, which is 48% below median its 10-year median of 14.28 and 210.5% above the Healthcare Providers & Services industry median of 2.38. Alibaba Health Information Technology's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Alibaba Health Information Technology (ALBBY), the current Altman Z-Score is 7.39 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alibaba Health Information Technology (ALBBY) Overvalued in 2026?
Based on GuruFocus' analysis, Alibaba Health Information Technology stock appears to be undervalued.
The current stock price of $7.92 is trading 40.7% below its estimated GF Value™ of $13.36.
GuruFocus considers Alibaba Health Information Technology to be Significantly Undervalued.
Key valuation signals for ALBBY:
Altman Z-Score: 7.39 (48% below median its 10-year median of 14.28)
GF Value™: $13.36 vs. price of $7.92 (40.7% below fair value)
Industry Position: 210.5% above the Healthcare Providers & Services median (#98 of 657)
No single metric tells the full story. See the ALBBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alibaba Health Information Technology Business Description
Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on. The company operates both a third-party B2C service, or 3P, and its own direct-to-consumer business, or 1P, with its own inventory, which can both be accessed by Alibaba's Tmall app and Alipay. The company also provides online consultation services in a separate app although its e-commerce businesses remain its core competency in the long-term. E-commerce accounted for 93% of revenue in fiscal year 2022. We estimate that AliHealth holds about 45% of market share in the industry in terms of GMV. AliHealth is 63.74% owned by its parent company, Alibaba Group.
73GF Score
Get the complete analysis for ALBBY
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALBBY has been successfully added to your 
